SynthesisBlood transfusion = Trasfusione del sangue
When is ABO-incompatible plasma safe to transfuse? Defining an empirical estimation of anti-A/anti-B in ABO incompatible plasma-containing blood products.
Synthesis in Blood transfusion = Trasfusione del sangue. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cryoprecipitate utilisation, shortages and institutional policies in the United States: A survey of practices and policies.Transfusion medicine (Oxford, England) · 2026Article
- From Donation to Innovation: New Blood-Derived Products.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis systematic review aims to determine the loads of anti-A and anti-B in plasma-containing blood products that can safely be transfused to adults. MATERIALS AND
methodsA comprehensive literature search was performed in PubMed, including studies dating back to 1940 until January 1
resultsWe identified HTRs with a wide-ranging antibody content, with the lowest being a platelet product with an antibody content of 12,480 AU for both IgM and IgG. However, we could establish that a calculated cutoff of 10,000 AU for IgM as well as 30,000 AU for IgG in plasma could be considered safe for transfusion. DISCUSSION: While titer is considered the gold standard when evaluating risk for HTR, the total volume of plasma transfused is rarely considered. Here, we recommend calculating an antibody content by using a titer and plasma volume of the unit(s) intended for transfusion as a good risk mitigation strategy for reducing HTRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.